BioRestorative Completes cGMP ISO-7 Manufacturing of BRTX-100 for Phase II Trial
BRTX•BioRestorative Therapies completed manufacturing for its BRTX-100 Phase 2 clinical trial in its cGMP ISO-7 certified facility, advancing its stem cell therapy for chronic lumbar disc disease. The full in-house platform spanning cell sourcing to final formulation is designed to ensure scalable, high-quality biologic production and lower manufacturing costs.
1. Manufacturing Milestone
BioRestorative Therapies has finished manufacturing the clinical supply of BRTX-100 for its Phase 2 trial at a cGMP ISO-7 certified facility in Melville, N.Y. This milestone supports the ongoing study in chronic lumbar disc disease and underscores the company’s operational capabilities.
2. Integrated Regenerative Platform
The company’s vertically integrated platform covers cell sourcing, processing, formulation and final manufacturing under one roof. This end-to-end control ensures consistency, traceability and high biological integrity across both therapeutic and BioCosmeceutical products.
3. Strategic Advantages and Cost Impact
In-house production reduces external reliance, lowers manufacturing expenses and improves operating margins. The scalable infrastructure enables dual-path value creation by supporting near-term commercial biologics alongside long-term clinical programs.
